BioXcel Therapeutics Reveals Survival Data From Prostate Cancer Combo Therapy Trial

BioXcel Therapeutics Inc (NASDAQ: BTAI) announced overall survival (OS) data from its Phase 2 trial of BXCL701 in combination with Merck & Co Inc’s (NYSE: MRK) Keytruda (pembrolizumab) in patients with metastatic castration-resistant prostate cancer of adenocarcinoma phenotype, the most common form of the disease. As of a September 6, 2023 data cutoff, evaluable patients with adenocarcinoma (n=29) showed a median OS of 15.5 months and a 12-month survival rate of 59%. Also Read:Schizophrenia Player BioXcel’s Drug Faces Funding Headwinds, Analyst Downgrades Stock. The company reported a RECIST p…

Read More